论文部分内容阅读
目的:了解晚期胃癌术前应用卡培他滨联合紫杉醇方案进行新辅助化疗的疗效和毒副反应。方法:84例晚期胃癌患者中,试验组42例术前接受辅助化疗:卡培他滨1650mg/(m2.d),口服,d1～d14;紫杉醇175mg/(m2.d),静脉滴入,d1。每3周为1个周期,连用2个周期,新辅助化疗结束2～4周后行手术治疗。对照组42例在确诊后2周内行手术治疗。84例患者均行胃癌根治术(D2式淋巴结清除)。结果:试验组和对照组术后复发率分别为35.7%(15/42)和61.9%(26/42),2年生存率分别为59.5%(25/42)和19.0%(8/42),两组比较差异有统计学意义,χ2值分别为5.765和14.424,P值分别为0.016和0.001。试验组和对照组中位生存期分别为24.2和12.6个月。结论:术前应用卡培他滨联合紫杉醇方案进行新辅助化疗是目前治疗晚期胃癌较理想的方案。
Objective: To understand the curative effect and toxicity of neoadjuvant chemotherapy before capecitabine combined with paclitaxel in advanced gastric cancer. Methods: Among 84 patients with advanced gastric cancer, 42 patients in the experimental group received adjuvant chemotherapy before surgery: capecitabine 1650mg / (m2.d) orally, d1 ~ d14, paclitaxel 175mg / (m2.d) d1. Every 3 weeks for a cycle, once every 2 cycles, neoadjuvant chemotherapy after 2 to 4 weeks after surgery. The control group of 42 patients underwent surgery within 2 weeks after diagnosis. All 84 patients underwent radical gastrectomy (D2-type lymph node dissection). Results The recurrence rates of the two groups were 35.7% (15/42) and 61.9% (26/42), respectively. The 2-year survival rates were 59.5% (25/42) and 19.0% (8/42) , The difference between the two groups was statistically significant, χ2 values were 5.765 and 14.424, P values were 0.016 and 0.001. The median survival time was 24.2 and 12.6 months in the experimental and control groups, respectively. Conclusion: Preoperative application of capecitabine combined with paclitaxel neoadjuvant chemotherapy is the ideal treatment for advanced gastric cancer.